Why Is Option Care Health (OPCH) Stock Down -27% Today?
Key Takeaways
- OPCH shares are plunging approximately 27% in premarket trading on April 30, 2026, from a prior session close of $26.87 to roughly $19.62
- The primary catalyst is a significant revenue miss in Q1 2026, with net revenue of $1.35 billion coming in well below the Wall Street consensus estimate of approximately $1.40 billion
- Management also cut the full-year 2026 revenue guidance sharply, reducing the range from the prior $5.8 billion–$6.0 billion to a revised $5.675 billion–$5.775 billion
- Adjusted EBITDA fell 6.3% year-over-year to $104.8 million, reflecting mounting cost pressures and an accelerating drag from Stelara biosimilar conversions
- The revenue guidance reduction at the midpoint represents a cut of roughly $175 million, signaling that headwinds from drug pricing and biosimilar substitution are more severe than previously disclosed
- Traders are watching the 8:30 a.m. ET earnings call for detail on the magnitude and duration of the Stelara impact and any updated commentary on the organic growth outlook
Opening Summary
Option Care Health, Inc. (OPCH) is one of the largest independent providers of home and alternate-site infusion therapy services in the United States, delivering intravenous medications and related nursing support to patients with chronic and acute conditions outside of traditional hospital settings. Shares are collapsing approximately 27% in premarket trading on April 30, 2026, sliding from the prior session's closing price of $26.87 to roughly $19.62 after the company reported Q1 2026 financial results before the market open. The earnings-driven selloff reflects both a meaningful revenue shortfall versus expectations and a significant reduction to the company's full-year guidance, driven by a far more severe-than-anticipated drag from Stelara biosimilar conversions.
Q1 2026 Earnings: Revenue Miss Triggers Severe Reaction
OPCH reported Q1 2026 net revenue of $1,350.7 million, a 1.3% year-over-year increase but sharply below the FactSet consensus estimate of approximately $1.40 billion — a miss of roughly $50 million, or about 3.5%. Adjusted diluted EPS came in at $0.40, flat year-over-year and roughly in line with estimates, offering little comfort. The deeper concern lies in profitability: Adjusted EBITDA declined 6.3% to $104.8 million, while GAAP net income fell 3.0% to $45.3 million. Operating cash flow was negative at -$12.1 million for the quarter, adding further pressure to investor confidence heading into the rest of the year.
Guidance Cut: The Core Catalyst Behind the Plunge
The more damaging element of the Q1 2026 release was the substantial revision to full-year guidance. OPCH lowered its 2026 net revenue outlook to $5.675 billion–$5.775 billion, down from the prior $5.8 billion–$6.0 billion range affirmed as recently as February. The midpoint of the new range sits at $5.725 billion, roughly $175 million below the midpoint of the previous guidance. Full-year Adjusted EBITDA guidance was also narrowed to $480 million–$505 million — maintaining the range but implying limited upside expansion given Q1 underperformance. The full-year Adjusted diluted EPS range of $1.82–$1.92 was also reaffirmed, though investors viewed the revenue cut as the overriding signal.
Stelara Biosimilar Headwind: Worse Than Expected
A central factor weighing on OPCH throughout 2025 and now accelerating in 2026 is the rapid adoption of biosimilar versions of Stelara (ustekinumab), a high-value biologic used to treat chronic inflammatory conditions. As patients transition from the branded reference product to lower-cost biosimilars, OPCH collects lower reimbursement per patient, directly compressing both revenue and gross profit. The company had previously estimated an annual revenue headwind of approximately $65 million–$70 million from this transition. The Q1 results and guidance cut suggest the pace of biosimilar conversion has accelerated meaningfully beyond those earlier projections, explaining why the guidance reduction exceeds what analysts had modeled. Management's language around "decisive actions to reaccelerate growth" underscores the severity of the challenge.
Market Context and Trading Activity
OPCH entered the session in a technically weakened position, already trading near its 52-week lows and roughly 25% below the analyst consensus price target of approximately $37.00. The stock had lost more than 3% on April 29 alone, suggesting some positioning ahead of the print. The premarket volume surge accompanying the 27% decline is well above any historical average, consistent with an institutional-driven flush following a dual shock of a revenue miss and a guidance cut. The broader healthcare services sector and home infusion peers will also be watched for sympathy moves. Health and specialty infusion ETFs may come under associated pressure as investors reassess reimbursement risk across the category. The broader market, while facing its own macro cross-currents from trade and rate policy, is not driving this move — OPCH's decline is company-specific and earnings-driven.
Trending AI Robots
For traders looking to navigate sharp, earnings-driven dislocations like today's move in OPCH, Tickeron's Trending AI Robots page provides a curated view of the platform's highest-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-powered bots spanning thousands of tickers, strategies, and timeframes — but only the strongest performers are featured in the Trending section. Bots differ across key dimensions including trading style (momentum, mean reversion, swing), holding period, performance metrics, and the specific symbols they trade. Whether a trader is responding to a gap-down like today's or positioning for a longer-term recovery, the Trending AI Robots section helps cut through the noise and identify bots with a demonstrated edge in live market conditions. Traders seeking a data-driven approach to volatile environments are encouraged to explore the full offering.
What Comes Next for OPCH
The immediate focus will be on OPCH's 8:30 a.m. ET earnings call on April 30, 2026, where management is expected to provide detailed commentary on the pace of Stelara biosimilar adoption, the trajectory of chronic therapy volumes, and how the company plans to reaccelerate organic growth in the back half of the year. Investors will scrutinize whether the revised guidance range has adequately captured the remaining Stelara headwind or whether further cuts remain possible. Analysts who had been broadly bullish — with a consensus Moderate Buy and an average price target of approximately $37.00 — will likely revisit their models materially. Key upcoming data points include Q2 2026 results (expected in late July), any updates on M&A or capital allocation, and broader developments in specialty pharmacy reimbursement policy. Macro risks, including potential Medicaid or Medicare reimbursement changes under current legislative discussions in Washington, represent an additional variable that could weigh on the stock's recovery timeline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
OPCH's Stochastic Oscillator remains in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPCH advanced for three days, in 177 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
OPCH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 152 of 217 cases where OPCH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OPCH as a result. In 67 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for OPCH turned negative on September 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 33 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
OPCH moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OPCH crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPCH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. OPCH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.723) is normal, around the industry mean (208.195). P/E Ratio (17.348) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (1.101) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPCH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of home and alternate site infusion services.
Industry HospitalNursingManagement
Advertisement